Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
August 07 2019 - 1:00PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical
company focused on the development of therapeutic drugs for the
treatment of liver disease arising from non-alcoholic
steatohepatitis (“NASH”) and chronic viral infection, today
announced that Dr. Stephen Harrison has joined its Scientific
Advisory Board.
“We are honored to have Dr. Harrison, an
internationally recognized hepatologist (liver disease expert),
join our Scientific Advisory Board,” commented Dr. Carol Brosgart,
Clinical Professor of Medicine in the Divisions of Global Health
Sciences, Biostatistics and Epidemiology in the Department of
Medicine at the University of California, San Francisco and Chair
of the Company’s Scientific Advisory Board. “With his extensive
experience in chronic hepatitis and fatty liver disease, or NAFLD,
and NASH, Dr. Harrison joins us at an opportune time, as we prepare
for CRV431 to enter the clinic as a potential treatment for NASH
and continue to progress its clinical development more broadly in
liver disease.”
“I am looking forward to working with the Hepion
team to develop CRV431, a promising candidate with the potential to
treat not only hepatitis and NASH, but other diseases in which
fibrosis plays a role,” commented Dr. Harrison.
Dr. Harrison is currently a Visiting Professor
of Hepatology at the Radcliffe Department of Medicine, University
of Oxford. He is also the Medical Director for Pinnacle Clinical
Research and the President of Summit Clinical Research.
Dr. Harrison is a peer-reviewer for more than 20
medical journals. He is internationally known for studies in
hepatitis C and non-alcoholic fatty liver disease with more than
200 peer reviewed publications in these fields. Dr. Harrison
previously served as a Professor of Medicine at the Uniformed
Services University of the Health Sciences and as Associate Editor
for Hepatology and Alimentary Pharmacology and Therapeutics. Most
recently, Dr. Harrison served as a Colonel in the United States
Army, retiring in 2016 to conclude 20 years of dedicated service to
his country. During his army tenure, he served as the Director of
Graduate Medical Education at Brooke Army Medical Center, Associate
Dean for the San Antonio Uniformed Services Health Education
Consortium, and Gastroenterology Consultant to the Army Surgeon
General.
Dr. Harrison earned his medical degree from the
University of Mississippi School of Medicine. He completed his
internal medicine residency and gastroenterology fellowship at
Brooke Army Medical Center and a 4th year advanced liver disease
fellowship at Saint Louis University. He is board certified in both
Internal Medicine and Gastroenterology.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical stage
biopharmaceutical company focused on the development of targeted
therapies for liver disease arising from non-alcoholic
steatohepatitis (NASH) and chronic hepatitis virus infection (HBV,
HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver
fibrosis and hepatocellular carcinoma tumor burden in experimental
models of NASH. Preclinical studies also have demonstrated
antiviral activities towards HBV, HCV, and HDV through several
mechanisms. These diverse therapeutic activities result from
CRV431’s potent inhibition of cyclophilin enzymes, which are
involved in many disease processes. Currently in clinical phase
development, CRV431 shows potential to play an important role in
the overall treatment of liver disease - from triggering events
through to end-stage disease.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be
identified by the use of forward-looking words such as
“anticipate,” “believe,” “forecast,” “estimated,” and “intend,”
among others. These forward-looking statements are based on Hepion
Pharmaceuticals’ current expectations and actual results could
differ materially. There are a number of factors that could
cause actual events to differ materially from those indicated by
such forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. Hepion
Pharmaceuticals does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the
year ended December 31, 2018 and other periodic reports filed with
the Securities and Exchange Commission.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect:
(646) 274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Sep 2023 to Sep 2024